Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 14Ovarian Neoplasms 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Triple Negative Breast Neoplasms 5Lung Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Inflammatory Breast Neoplasms 3Adenocarcinoma of Lung 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Melanoma 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Adenocarcinoma, Bronchiolo-Alveolar 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Turcot syndrome 1Thrombocytosis 1Stages II-III Breast Cancer 1Stage IIIA Lung Non-Small Cell Cancer AJCC v7 1Stage IA Uterine Sarcoma 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Primary Myelofibrosis 1

Interventions

Nivolumab 2tislelizumab 1avelumab 1Taxes 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Ipilimumab 1Fluorouracil 1Carboplatin 1Capecitabine 1Biopsy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Turcot syndrome × Taxes × Clear all
NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡